The FDA found "objectionable conditions or practices" at Neuralink's animal testing facilities, prompting the agency to recommend remediation measures without severe regulatory actions.
Despite the citations regarding documentation practices, the FDA confirmed that no violations jeopardized device safety, emphasizing that concerns did not require regulatory intervention.
Collection
[
|
...
]